23 de octubre de 2019
30 de noviembre de 2009

Sanofi-aventis: Multaq(R) Approved in the European Union for Patients With Atrial Fibrillation (y 2)


References:
1 Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial
fibrillation in adults: national implications for rhythm management
and stroke prevention: the AnTicoagulation and Risk Factors in Atrial
Fibrillation (ATRIA) Study. JAMA 2001; 285:2370-5.
2 Lloyd-Jones et al. Lifetime Risk for Development of Atrial
Fibrillation: The Framingham Heart Study. Circulation. 2004;
110:1042-1046.
3 Fuster V et al. ACC/AHA/ESC 2006 guidelines for the management of
patients with atrial fibrillation. European Heart Journal (2006) 27,
1979-2030.
4 Benjamin EJ, Wolf PA, D'Agostino RB, Silbershatz H, Kannel WB, Levy D.
Impact of atrial fibrillation on the risk of death: the Framingham
Heart Study. Circulation 1998 Sep 8; 98(10):946-52..
5 Ringborg et all, Europace 2008 10; 400-411

FOR MORE INFORMATION PLEASE VISIT:
Dronedarone press office:
http://www.dronedarone-atrial-fibrillation-pressoffice.com

MEDIA CONTACT: Philippe BARQUET, Tel: +33(0)6-70-48-61-28, Email: philippe.barquet@sanofi-aventis.com